Obama Proposes Mostly Flat FY 2015 FDA Budget
This article was originally published in The Pink Sheet Daily
Executive Summary
Stakeholders indicate concern that the minimal increase will not adequately fund agency programs.
You may also be interested in...
Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows
CDER Director Janet Woodcock says user fee revenue will increase slowly, in part because some fees will not produce much revenue until the biosimilar industry expands.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.